Neogen updates timeline on Zoetis genomics sale amid antitrust review
Neogen said regulatory clearance for its genomics business sale to Zoetis is now expected to conclude in early 2027 after Zoetis offered to divest assets in Australia.
SEC filing
3 stories
Neogen said regulatory clearance for its genomics business sale to Zoetis is now expected to conclude in early 2027 after Zoetis offered to divest assets in Australia.
SEC filing
Neogen Corporation filed an amended report to disclose that shareholders approved an updated omnibus equity incentive plan at the company's October 1, 2026 annual meeting.
SEC filing
Neogen lifted full-year guidance after first-quarter core revenue grew 8.1% and said Petrifilm manufacturing and a pending Zoetis divestiture remain on schedule.
SEC filing (11)